[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@jeromeleonard5 Avatar @jeromeleonard5 jerome leonard

jerome leonard posts on X about $idya, combo, $tngx, $ucb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks currencies cryptocurrencies finance

Social topic influence $idya #12, combo, $tngx, $ucb, $bmy, $cere, take the, $gsk, $zlab, 1k

Top assets mentioned IDEAYA Biosciences, Inc. Common Stock (IDYA) United Community Banks, Inc. (UCB) Bristol-Myers Squibb Co (BMY) Cere Network (CERE) GSK plc (GSK)

Top Social Posts #

Top posts by engagements in the last XX hours

"My takeaway of $idya mtap update: Half the XXX dose isn't enough 30mg dose with trodelvy shows pot synergies with regard to ORR. Albeit low N & uPR needs to confirm. 30mg dose had a mono mpfs of approx 6m. If this translates into the combo with higher ORR they have an approvable combo for sure. Also DL2 is very well tolerated"
X Link @jeromeleonard5 2025-09-08T16:51Z 2265 followers, 3770 engagements

"@RandomBioThinks Yet another shitty close. But silver lining is 1y+ from now well be nearing poc on so many 1st in class mono and combo therapies for which there is no equal out there on the onco side. $idya will be eventually be rerated as a platform company"
X Link @jeromeleonard5 2025-10-03T20:28Z 2265 followers, XXX engagements

"$bmy prmt5 going after 1L mtap Pdac $tngx Study named: Moutain-TAP30 😆"
X Link @jeromeleonard5 2025-10-09T05:07Z 2268 followers, 1676 engagements

"At least $cere management was smart enough to take the $ when they could"
X Link @jeromeleonard5 2025-09-28T18:44Z 2265 followers, 2311 engagements

"$gsk prmt5 bites the dust"
X Link @jeromeleonard5 2025-09-17T12:06Z 2265 followers, 2190 engagements

"Neoadjuvant daro BT data will be top nodge as well tomorrow. Vision improvement on Daro pre BT should derisk the neo-adj p3 down the road in the same way they derisked the enocluation part a year ago. $idya"
X Link @jeromeleonard5 2025-09-07T17:49Z 2265 followers, 1247 engagements

"@JacobPlieth @NotthatkindofDr Started dosing in jan/feb. Most likely asco 26"
X Link @jeromeleonard5 2025-10-13T14:16Z 2265 followers, XXX engagements

"ORR dropping from a cliff for 3rd line + patients should make it clear which one has the best eff. If we focus on the XXX dose $zlab is losing very deep resp pretty fast. For me the gr3 ae profile just look too good and this will come at cost of exposure levels & durability"
X Link @jeromeleonard5 2025-09-09T14:36Z 2265 followers, 1270 engagements

"397+ trodelvy $idya"
X Link @jeromeleonard5 2025-09-08T10:53Z 2265 followers, 6637 engagements

"@Quantumup1 Assuming 400K per patient for 6m neoadjuvant daro gets you 400m with just 1K patient. There should be at least 4K patients in US alone. +70% of patients should complete the 6m. Neoadjuvant opportunity is much bigger than Jmp assumptions. $idya"
X Link @jeromeleonard5 2025-10-07T14:21Z 2265 followers, XXX engagements

"@nociFTW Could and should have done something big a long time ago to derisk the pipe. Still could but they most certainly wont in a bull market"
X Link @jeromeleonard5 2025-10-15T17:14Z 2265 followers, XXX engagements

"@BioValues @Amylucio2009 IF they're moving so fast through the doses with a t-cell engager it isn't a good sign. CRC only focus also isn't a good one"
X Link @jeromeleonard5 2025-10-14T15:29Z 2265 followers, XXX engagements

"@bioinvestor24 @NotGenentech XXX has +30% ORR and +6m mfs isn't this what you and $tngx ceo are wishing for XXX Only difference is that $idya ceo doesn't think this warrants a mono P3. And yes low N but if you look at ORR & how fast those resp are happening its a clear proof of synergies as intended"
X Link @jeromeleonard5 2025-09-27T18:42Z 2265 followers, XXX engagements

"Would surprise me if $idya didn't have an additional edge for that 3rd mtap program. tbc"
X Link @jeromeleonard5 2025-09-11T15:19Z 2265 followers, 1392 engagements

"Another smart move by $idya management to opt for a dual and conditional 1+1 format for their ptk7+B7H3 adc"
X Link @jeromeleonard5 2025-09-16T09:33Z 2265 followers, 4737 engagements

"@BioValues @Amylucio2009 You do get it that the rapid dose escalation and the narrowing of the indication to only crc are two opposites at this stage of development. Makes no sense at all"
X Link @jeromeleonard5 2025-10-14T15:34Z 2265 followers, XXX engagements

"@bioinvestor24 @NotGenentech No they didnt. Prmt5 add on has been in the pipe for a long time. Again there hasnt been any mono prmt5 agent that has been pushed for mono approval. Im sure XXX is very special yet ceo comments they are aspiring for same orr as the bmy compound. Differentiation"
X Link @jeromeleonard5 2025-09-27T18:57Z 2265 followers, XXX engagements

"@NotthatkindofDr @JacobPlieth Id wait for the gsk update before drawing any conclusions on wrn. Data will be better than roche"
X Link @jeromeleonard5 2025-10-13T12:58Z 2265 followers, XXX engagements